Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | ||
Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | ||
Alimta | Pemetrexed | Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Alecensaro | Alectinib | Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Alecensaro | Alectinib | Locally advanced or metastatic ALK+ NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Complete |